New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Cognis Launches Super Xangold® --- Eye Health Ingredient Delivering a 5 to 1 Ratio of Natural Lutein Esters and Zeaxanthin Esters

Las Vegas, Nov. 6, 2007 – Cognis Nutrition & Health is keeping its eye on visual health with the launch of its new Super Xangold®, the only eye health ingredient with a 5 to 1 ratio of lutein esters and zeaxanthin esters. This is the identical ratio of ingredients being used in the landmark Age Related Eye Disease Study II (AREDS II).

Super Xangold®, a proprietary blend of natural lutein esters and zeaxanthin esters, contains the same average 5 to 1 ratio found in natural dietary sources. It is patent protected by U.S. Patent #6,191,293 and EU Patent #EP1073694B1, providing manufacturers assurance that their product will be unique to the marketplace. The macular pigment is made up entirely of the carotenoids lutein and zeaxanthin and is located at the center of the retina, at the site of highest visual acuity. Super Xangold® is available as a 15% suspension in olive oil, packaged in a 10 kg container.

“With the rapidly aging population, Super Xangold® natural lutein esters and zeaxanthin esters are the ideal combination to help maintain optimal eye health,” said Rob Bailey, Marketing Manager, Cognis Nutrition & Health. “We know that advancing age is the leading cause of vision impairment and blindness, and Cognis’ research team is working hard to deliver the finest ingredients formulators can use to create safe and effective eye health products.”

Page 1 of 2
About The Xangold® Product Line of Eye Health Ingredients
Super Xangold®, a proprietary blend of natural lutein esters and zeaxanthin esters, is the newest ingredient to join Cognis’ Xangold® product line of eye health products. Super Xangold® is another example of Cognis’ commitment to providing The Gold Standard™ for natural eye health success.

Xangold® natural lutein esters is a highly bioavailable source of lutein and appeals to manufacturers for its stability and long-lasting potency. Xangold® is extracted from marigold flowers grown specifically for Cognis, and available in two forms: oils for soft gel capsules and micro-encapsulated beadlets for tablets or functional food applications. Scientific studies have consistently shown that lutein from lutein esters has equivalent bioavailability, and may be even superior to that of free lutein. The Xangold® product line offers non-GMO, kosher and vegetarian-source lutein esters for a variety of product applications.

For information in North America about Super Xangold® natural lutein esters and zeaxanthin esters, please call 800-673-3702 to place an order, e-mail, or fax 513.482.3576.

About Cognis:
Cognis ( is a worldwide supplier of innovative specialty chemicals and nutritional ingredients, with a particular focus on the areas of wellness and sustainability. The company employs about 8,000 people, and it operates production sites and service centers in 30 countries. Cognis has dedicated its activities to a high level of sustainability and delivers natural source raw materials and ingredients for food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Another main focus is on products for a number of other industries, such as coatings and inks, lubricants, textiles, as well as agriculture and mining. The subsidiary Pulcra Chemicals offers specialized chemical products and process expertise to customers in the fiber, textile, and leather industries. Cognis also holds a 50-percent stake in the joint venture Cognis Oleochemicals, one of the world’s leading manufacturers of oleochemicals. Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and SV Life Sciences. In 2006, Cognis recorded sales of 3.37 billion euros and an Adjusted EBITDA (operating result) of 394 million euros.


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.